
    
      This is a multicenter,open-label,prospective study of Aripiprazole use in patients with
      schizophrenia and bipolar disorder.

      Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of
      Aripiprazole by physician's assessment.

      Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of
      Aripiprazole by physician's assessment.

      This study will be continued for 6 years. The final report of Aripiprazole PMS will be
      submitted to KFDA on December 28, 2009.
    
  